HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.

Abstract
The oral drug miltefosine (MIL) was introduced in the Indian subcontinent in the year 2002 for the treatment of visceral leishmaniasis (VL). However, recent reports on its declining efficacy and increasing relapse rates pose a serious concern. An understanding of the factors contributing to MIL tolerance in Leishmania parasites is critical. In the present study, we assessed the role of the lipase precursor-like protein (Lip) in conferring tolerance to miltefosine by episomally overexpressing Lip in Leishmania donovani (LdLip++). We observed a significant increase (∼3-fold) in the MIL 50% inhibitory concentration (IC50) at both the promastigote (3.90 ± 0.68 µM; P < 0.05) and intracellular amastigote (9.10 ± 0.60 µM; P < 0.05) stages compared to the wild-type counterpart (LdNeo) (MIL IC50s of 1.49 ± 0.20 µM at the promastigote stage and 3.95 ± 0.45 µM at the amastigote stage). LdLip++ parasites exhibited significantly (P < 0.05) increased infectivity to host macrophages and increased metacyclogenesis and tolerance to MIL-induced oxidative stress. The susceptibility of LdLip++ to other antileishmanial drugs (sodium antimony gluconate and amphotericin B) remained unchanged. In comparison to LdNeo, the LdLip++ parasites elicited high host interleukin-10 (IL-10) cytokine expression levels (1.6-fold; P < 0.05) with reduced expression of the cytokine tumor necrosis factor alpha (TNF-α) (1.5-fold; P < 0.05), leading to a significantly (P < 0.01) increased ratio of IL-10/TNF-α. The above-described findings suggest a role of lipase precursor-like protein in conferring tolerance to the oral antileishmanial drug MIL in L. donovani parasites.
AuthorsDeepak Kumar Deep, Ruchi Singh, Arpita Kulshrestha, Saima Wajid, Poonam Salotra
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 62 Issue 12 (12 2018) ISSN: 1098-6596 [Electronic] United States
PMID30297367 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 American Society for Microbiology.
Chemical References
  • Antiprotozoal Agents
  • Cytokines
  • Protozoan Proteins
  • Phosphorylcholine
  • miltefosine
  • Lipase
Topics
  • Animals
  • Antiprotozoal Agents (pharmacology)
  • Cytokines (metabolism)
  • Drug Resistance (drug effects, genetics)
  • Female
  • Host-Pathogen Interactions (drug effects, physiology)
  • Inflammation (metabolism, parasitology)
  • Leishmania donovani (drug effects, genetics, pathogenicity)
  • Leishmaniasis, Visceral (drug therapy, parasitology)
  • Lipase (metabolism)
  • Macrophages (drug effects, parasitology)
  • Mice, Inbred BALB C
  • Oxidative Stress
  • Phosphorylcholine (analogs & derivatives, pharmacology)
  • Protozoan Proteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: